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Aims. We aimed to identify an antidepressive compound found in traditional Chinese medicine (TCM) by a new approach called
ethnopharmacokinetic- and activity-guided isolation (EAGI). Methods. The new approach targets an unknown chromatographic
peak produced by an absorbed compound found in oral Chaihu-Shugan-San (CSS) taken by patients with depression. Once the
compound was isolated from Fructus Aurantii (FA), spectral data was employed to identify the compound. The eﬀects of this
compound, FA, and CSS on depressive behaviors were investigated. Results. The identiﬁed compound was merazin hydrate (MH)
according to the new approach. MH, FA, and CSS signiﬁcantly reduced immobility time and increased locomotor activity. The
eﬀects of MH, FA and CSS were similar to Fluoxetine at high doses. Conclusion. MH, a compound whose antidepressive eﬀect is
similar to FA and CSS, was isolated for the ﬁrst time from FA via targeting its corresponding unknown chromatographic peak, and
its antidepressive eﬀect was compared with FA or CSS. These ﬁndings highlight the potential for drug R&D and pharmacological
research of ∼100,000TCMs.
1.Introduction
Currently, drug R&D is highly challenging for scientiﬁc
and economical reasons because of the high rate of failure,
massive spending, and lengthy research period (1960s) [1].
Many phytochemicals have been isolated by activity-guided
isolation(AGI)fromherbsorplants[2]andshowntoexhibit
poor pharmacokinetic absorption [3]. There is limited data
regarding the absorption properties of the compounds
isolated from their parent herbs [2]a sw e l la sb i o a c t i v e
comparisons with the parent herbs [2].
It is important to determine a method that can success-
fully hit on a promising lead from a single herb or traditional
Chinese medicine (TCM), which has been clinically used
for more than 8000 years [4]. Interestingly, unknown
chromatographic peaks in the blood and urine obtained
from subjects who orally consumed TCMs provided the ﬁrst
leads [5]. During our pharmacokinetic study, an unknown
chromatographic peak also appeared in blood samples
30min after patients had been dosed with Chaihu-Shugan-
San (CSS), a famous TCM which has been used for several
centuries to improve some symptoms similar to depression2 Evidence-Based Complementary and Alternative Medicine
[6]. Our goal was to isolate the pharmacokinetic compound
corresponding to the unknown chromatographic peak and
determine the parent herb. The ethnopharmacokinetic- and
activity-guided isolation (EAGI) method allows for the
identiﬁcation of this compound.
We aimed to isolate a new antidepressive compound
from a herb in CSS via targeting the unknown absorbed
compound found in the blood from patients with depression
followingoralCSSandcomparingitsactivitywiththeparent
herb and CSS.
2. Experimental
2.1. Crude Drugs, Chemicals, and Reagents. CSS contains
Bupleurum Root, Pericarpium Citri Reticulatae, Rhizoma
Chuanxiong, Rhizoma Cyperi, Fructus Aurantii (FA), Paeo-
nia, and Radix Glycyrrhizae in a ratio of 8:5:5:5:5:3:2-
based dry weight. All of these compounds were purchased
from the pharmacy at Xiangya Hospital (Changsha, China)
and identiﬁed. The voucher specimens were deposited at
the Laboratory of Ethnopharmacology in Xiangya Hospital.
T h e7h e r b sw e r eb o i l e dt w i c ei nw a t e r( 1 : 1 2 ,g / m L )f o r
1h. The blended supernatants of two extracts were then
lyophilized (the yield = 18.2%) for each of the herbs treated.
FA, which had been known to contain an unknown peak,
was lyophilized for pharmacological study, and its yield was
12.6%. The lyophilized powders of CSS and FA were stored
at 4◦C prior to use. The powders were dissolved in distilled
water (CSS, 0.03g/mL and FA, 0.002g/mL (w:v)) prior to
analysis pharmacological experiments.
Albiﬂorin, ferulic acid, paeoniﬂorin, liquiritin, naringin,
hesperidin, Neohesperidinn, isoliquiritigenin, glycyrrhizic
acid, alpha-cyperone, and 18-bata-glycyrrhizic acid were
purchased from the National Institute for the Control of
PharmaceuticalandBiologicalProducts(Beijing,China)and
used as reference chemicals to exclude known compounds
in CSS as part of the isolation procedure. Fluoxetine, which
is an accepted positive antidepressive control agent, was
purchased from Pharmacy of Xiangya hospital. Acetonitrile
and methanol (HPLC grade) were obtained from the Tedia
Company, Inc, Fairﬁeld, Ohio (USA). The other reagents
were of analytical grade. House triple-distilled water from
silica glass equipment was also used. All of the samples for
UPLC or HPLC were ﬁltered through 0.22μm ﬁlm prior to
injection in the UPLC or HPLC.
2.2. Experimental Design. The EAGI approach included
targeting the unknown chromatographic peak absorbed
from the gut following oral consumption of CSS by depres-
sive patients and ascertaining its herbal source. Then the
unknown compound was isolated and identiﬁed and its
antidepressive eﬀects were compared with its parent herb or
CSS.
2.3. Targeting an Unknown Chromatographic Peak in Patient
Plasma and Detecting Its Herbal Source
2.3.1. The Patient Enrollment and Administration. The study
protocol was approved by The Medical Ethics Committee
of Xiangya Hospital, China. Three patients experiencing a
major depressive episode without psychotic features (males;
mean age, 25.67 years; mean body weight, 62.2kg) were
enrolled in the present study according to a previously
published protocol [7]. Informed consent was obtained from
the patients. The oral dose of CSS (0.52g/kg) in the present
study is consistent with a previously published protocol [8].
The lyophilized powder of CSS was resolved to 1g/mL (w:v)
for each patient. The patients fasted for 12h with free access
to water prior to drug administration.
2.3.2. Sample Collection and Preparation. Blood samples
(5mL) were obtained before and 30min after oral CSS via
venipuncture. The plasma (2mL) and methanol (3.4mL)
were placed in a centrifuge tube (5mL). The solution
was mixed well by ultrasound vortexed for 5min. Then
the denatured protein precipitated and was separated by
centrifugation at 3000g for 15min at 4◦C. The supernatant
was transferred to another tube and evaporated to dryness in
awaterbathat50◦Cunderastreamofnitrogen.Theresidues
were reconstituted in 50μL of methanol with vortexing for
1min, and the centrifugation procedure was repeated. Then
6.0μL of the methanol solution was injected into UPLC for
analysis.
2.3.3. UPLC-MS Determination of an Unknown Peak via
Excluding the Known Compounds. UPLC-MS/MS contained
a Waters Acquity UPLC system equipped with a quaternary
solvent delivery system, an autosampler ﬁtted with a 10μL
loop and a PDA optical detector for ultraviolet wavelengths
(190∼500nm). The separation was carried out on an acquity
BEN C18 column (100 × 2.1mm, 1.7μm, Waters, USA).
The mobile phase consisted of a solution of acetonitrile (70–
85%) and 0.5% acetic acid (30–15%) which was prepared
daily and degassed prior to use. The ﬂow rate of the pump
was 0.5mL/min, and the column temperature was set to
25◦C. During the analyses, 6μL of sample was injected by
the autosampler. The MS was performed on a Finnigan
TSQ (San Jose, CA, USA) mass spectrometer equipped with
an APCI interface. Mass spectrometric conditions were opti-
mized to achieve maximum sensitivity. The APCI conditions
were as follows: corona discharge voltage, 4.5kV; heated
capillary temperature, 330◦C; nebulization temperature,
450◦C; nitrogen was used both as sheath gas (70psi, 1psi =
6894.76Pa)andauxiliarygas(25a.u.).Argonwasusedasthe
collision gas with a collision energy of 35V. The data was
collected and processed using Empower TM Software.
Qualiﬁcations for known and unknown compounds
from herbs of CSS were performed in multiple channels in
the selected ion monitoring (SIM) mode using target ions
at [M-H]− m/z 479 for albiﬂorin [9], [M-H]− m/z 449 for
paeoniﬂorin [9], [M+H]+ m/z 193 for ferulic acid [10],
[M+Na]+ m/z 441 for liquiritin [11], [M-H]− m/z 579.1
for naringin [12, 13], [M-H]− m/z 609.4 for hesperidin
[14], [M-H]− m/z 255 for isoliquiritigenin [11], [M-H]−
m/z 611.0 for Neohesperidinn [14], [M+H]+ m/z 218 for α-
cyperone [15], [M-H]− m/z 469.5 for 18β-glycyrrhizic acid
[16],and[M+H]+ m/z278.0fortheunknown targetedpeak.
The retention time, UV spectra, and the target ions from theEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: The chemical structure of Merazin hydrate.
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Figure 2: Typical chromatograms MH. (A) chromatogram of a
blank plasma sample; (B) chromatogram of a plasma sample of
patient with depression taken 30min after oral administration of
CSS; (C) chromatogram of CSS; (D) chromatogram of FA; (E)
chromatogram of (1) Hesperidin, (2) Naringin, (3) Neohesperidin,
(4) Narirutin, and (5) Merazin hydrate.
chromatographic peaks obtained from blank plasma, ABCs-
contained plasma, CSS, various herb, and a special fraction
collected from Fructus Aurantii (FA) by a preparative
chromatographic system are provided in Section 2.4 and
were compared with the known reference chemicals. The
unknown compound and its parent herb were validated via
excluding peaks that corresponded to known compounds
and the parent herb, which was FA.
2.4. Isolation and Identiﬁcation of the Unknown Compound
2.4.1. FA Sample Preparation and Extraction. The air-dried
and powered fructiﬁcation of FA samples (2000g) were
ﬁrst soaked in 16000mL of 95% ethanol for 8h and then
extracted 3 times with the above solvent under reﬂux in
a9 0 ◦C water bath for 1.5h. After removing the organic
solvent from the blended solution in vacuo, an ethanol
extract (500g, wet weight) was performed. The latter
was reextracted once with 6000mL of ligarine to remove
hyperpolar substances. The ligarine extract concentrated in
vacuo was extracted 3 times with acetoacetate under reﬂux
heating for 2h. After concentrating the acetoacetate extract
in rotary evaporation, 50g of residue dissolved in 50mL
acetone was subjected to a silica gel CC (15 × 5cm i.d.) and
eluted with a gradient of ligarine/C4H8O2 (100:0 → 50:50)
to aﬀordonefraction.Theelutedextractwasconcentratedto
4420mg sample in vacuo. The 4420mg sample was dissolved
in 600mL of 50% methanol to yield the crude extract.
2.4.2. Isolation and Puriﬁcation of an Unknown Compound.
A waters Deltaprep Preparative Chromatography system
(Milford, MA) with Symmetryprep C18 (7μm, 19mm ×
150mm) column, a 7752i hand sampler, a PDA optical
detector for ultraviolet wavelengths (190∼500nm), and
a fraction collector was used along with the following
separating conditions: linear gradient CH3OH(A)/H2O( B )
(20:80 → 50:50): 0∼10min, 20% A; 10∼20min, 20∼
50% A; 20∼44min, 50% A; ﬂow rate: 10mL/min; column
temperature: 25◦C.
The supernatant of the FA extract (5mL) obtained in
Section 2.4.1 following centrifugation was ﬁltered through
0.22μm ﬁlm and subsequently isolated and puriﬁed by
preparative HPLC to obtain a special eluting fraction with a
speciﬁcretentiontimeselected.Thefractionwasdriedunder
rotary evaporation at 50◦C.
2.5. Identiﬁcation of the Unknown Compound. The spectral
data provided in Section 3.2 indicated that this compound
was Meranzin hydrate (Figure 1), which has been isolated for
the ﬁrst time from FA.
2.6. Antidepressive Comparison of MH and FA or CSS. Forty-
eight male Sprague-Dawley rats (200–240g) from SLAC
(Shanghai, China) conforming to the Regulations for the
Administration of Aﬀairs Concerning Experimental Animals
(1988) were approved by the Animal Experimental Center
for Central South University (Changsha, China). The rats
were housed in a temperature-controlled facility, with a 12h
light/dark cycle, and had unlimited access to food and water
for 7 days.
Rats were randomly assigned to groups as follows (n =
6): (1) vehicle: rats were gavaged 0.9% NaCl at one time; (2)
MH: rats were acutely gavaged a water solution containing
MH (7 and 14mg/kg) whose low dose induced a slight
eﬀect and the high dose had a more dramatic eﬀect; (3)
CSS: rats were acutely dosed with 10 and 30g/kg of CSS
extract consistent with a previously reported dose [17]; (4)
FA: rats were rapidly gavaged an aqueous solution of FA
(10 and 20g/kg) [10, 18]; (5) positive control: Fluoxetine
(20mg/kg) with a solution concentration of 0.66mg/mL was
orally administered to the rats [19]. The dosed volumes of
vehicle, MH, CSS, FA and Fluoxetine were 1.5mL/100g for
the rats [10] .T h es o l v e n t sh e r ea n di nSection 2.3.w e r e
prepared using distilled water.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: UV-absorptive spectrum of the ﬁve compounds: (a) Hesperidin, (b) Naringin, (c) Neohesperidin, (d) Narirutin, and (e) Merazin
hydrate.
A forced swimming test (FST) was performed according
to a previously published protocol [20]. The rats were
individually forced to swim twice at 24h intervals in a
cylinder (40cm high, 18cm in diameter) ﬁlled with water
(25◦C) up to 15cm deep. A 15min preswimming period
was followed 24h later by a 5min test period during
whichscoringwasperformed.Thebehavioralresponseswere
scored every 5 s based on swimming behavioral criteria; each
rat was judged to be immobile when it ceased struggling and
remainedﬂoatingmotionlessinthewater,makingonlythose
movements necessary to keep its head above water.
In the Open-ﬁeld test (OFT), each rat was individually
placed into the center of an open ﬁeld apparatus (40cm
height, 77cm × 77cm base divided into 49 squares 11cm ×
11cm each) to measure the locomotor activity (LMA) for
5min. The test was performed between 8:00 and 12:00.
A 60W light bulb provided the only source of illumination
in the testing room. The crossings number (CN, i.e., a ratEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: The preparative chromatogram of FA. 31.659min peak
was eluted and puriﬁed.
stepping from one square to another with its rear legs) was
regarded as the measurement parameter.
2.7. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n±
standard deviation. A database was set up with SPSS 15.0
software package (SPSS Inc. Chicago, USA). The diﬀerences
between two groups were analyzed by one-way ANOVA. A
probability of less than 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Determination of an Unknown Peak in Plasma, CSS, and
FA. In Figure 2, peak 5 was well separated using 280nm UV
light. Peak 5 was absent in blank plasma (A) while present
in the samples of plasma (B) which contained absorbed
compounds derived from CSS. CSS and FA also contained
this peak as shown in Figure 2 (C and D). Here, retention
times (12.19∼12.21min) and UV wavelength of peak 5 were
extremely similar (Figure 2). All of the target ions from peak
5 were the same ([M+H]+ m/z 278.0). Because there was no
corresponding reference compound for peak 5, peak 5 must
correspond to the unknown compound from FA.
The peaks of 1–4 from FA (Figure 2 D) were similar to
reference compounds with regard to retention time and UV
wavelength (Figure 2 E). They were hesperidin, narirutin,
naringin, and Neohesperidinn, respectively. The retention
time, UV proﬁle (Figure 3), and target ion of the other peaks
from CSS all corresponded to the reference compounds
described in Section 2.1 (data not shown).
3.2. Extraction and Identiﬁcation of Unknown Compound.
As shown in Figure 4, the peak (31.659min) of FA was
eluted using preparative chromatography, concentrated, and
puriﬁed to obtain 190.63mg of pure entity (the purity >
98%). The white crystalline material was identiﬁed as
meranzin hydrate as shown in Figure 1.
Results from UV, IR, MS, and NMR analysis are as
follows:
UV max (EtOH) nm: 212, 226, 262, 306nm; IR (KBr)
cm-1: 3200 (OH), 1710 (C=O), 1600, 1500(Ar), 1435(CH),
1250(C-O);1HNMR(1H-1HCOSY)δppm:7.95(1H,d,J =
9.5Hz, 4-H), 7.53 (1H, d, J = 7.5Hz, 5-H), 7.03 (1H, d, J =
7.5Hz, 6-H), 6.24 (1H, d, J = 9.5Hz, 3-H), 3.87 (3H, s,
OCH3), 4.15 (1H, brs, OH), 4.00 (1H, d, J = 5.9Hz, OH),
3.51 (1H, dd, J = 10.0, 2.5Hz, 2 -H), 2.90 (1H, dd, J = 12.0,
10.0Hz, 1 -Ha), 2.80 (1H, dd, J = 12.0, 2.5Hz, 1 -Hb), 1.14
(6H,s,2×CH3);13CNMR(100.6MHz,CDCl3)δ:26(C5  ),
25.5 (C4 ), 72.5 (C3 ), 76.8 (C2 ), 25.5 (C1 ), 56.5 (O-CH3),
117.4 (C10), 153.6 (C9), 108.3 (C8), 161 (C7), 113 (C6),
127.4 (C5), 145.2 (C4), 112.5 (C3), 161.0 (C2). EIMS m/z
(%): 278 (M+), 263, 245, 220, 189, 177(100), 131, 109.
(Found: C, 64.78; H, 6. 48. Calc. for C15H18O5: C, 64.75; H,
6.53). These data are consistent with a previously published
work [21].
3.3. Antidepressive Comparison between MH and FA or CSS.
The immobility time (s) and the number of crossings (n)
obtainedfortheratsthatwereforcedtoswimwerecompared
with sham (not swimming). The immobility time was found
to increase signiﬁcantly (immobility time, 120.9 ± 21.2
versus 168.2 ± 24.6), while the number of crossings was
reduced (122.4 ± 19.1v e r s u s9 4 .2 ± 18.7) for the drug
treatment groups in these studies. All of these data indicated
the success of depressive model.
Compared with the vehicle group, subacute administra-
tion of MH, FA, and CSS at a high dosage amount, dramat-
ically reduced the immobility time (s) (168.2 ± 24.6v e r s u s
123.3 ± 19.6, 128.6 ± 20.6, or 120.7 ± 21.4; all P values were
<0.05) as shown in Figure 5, which is similar to Fluoxetine
(125.4 ±23.6).
When gavaged with a high dose of MH, FA, and CSS,
all of the rats increased the number of crossings (125 ±
17, 116 ± 19 and 119 ± 22, resp.) compared with the vehicle
sample (94 ± 21; all P values were <0.05) as shown in
Figure 6. These data were similar to Fluoxetine (117 ± 21).
4. Discussion
MH, a compound isolated from FA for the ﬁrst time by
us (Chinese patent was applied in 2008 and authorized in
2011),andsomeofitsfurtherresearcheswerealsoperformed
and published [22, 23]. MH was readily absorbable into the
blood stream and could potentially lead to antidepressive
eﬀects which are similar to FA or CSS. An unknown chro-
matographic peak in patient blood following oral CSS was
targeted to ascertain its herbal source (Figure 2). Following
isolation, the structure was identiﬁed using spectral data
and its antidepressive eﬀects were compared with FA or CSS
(Figures 4 and 5). These steps illustrate the EAGI method.
This approach and its application can help to avoid the high
rate of failure for drug R&D due to poor pharmacokinetics
[3]a n de ﬃcacy [1, 24].
In chromatogram of Figure 2, MH was isolated from FA
via targeting absorption peak 5. Its absorption was unique
and its structure was the only unknown peak. Retention
times, UV spectra, and target ions of peak 5 in plasma, CSS,
and FA were nearly identical (Figures 2 and 3) and did not
corresponded to known reference chemicals. Using UV, IR,
MSandNMR,thestructureofthiscompoundwaselucidated
(Figure 1), which was consistent with previously published
work [21]. MH has been isolated from FA for the ﬁrst time.
Previously, MH was found in the peel of Phellolophium
madagascariense Baker [25], Magydaris tomentosa [26],6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of treatment with MH, FA, and CSS on the immobility of rats in the FST. Rats were treated with 0.9% saline (10mL/kg)
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Figure 6: Eﬀect of treatment with MH, FA, and CSS on locomotor activity evaluated in the open ﬁeld test. Rats were treated with 0.9%
saline (10mL/kg) (control), MH (7, 14mg/kg), FA (10, 20g/kg), CSS (11, 30g/kg) and Fluoxetine (20mg/kg).
∗P < 0.05 compared with the
vehicle group.
Citrus maxima fruit [27] ,M u r r a y ap a n i c u l a t a[ 28], and
Triphasia trifolia [21]. Is it surprising that MH has not been
previously isolated from FA [29, 30]. From Figure 2, the
four known compounds exhibited poor absorption. Tedious
isolations of the known compounds and a potentially high
failure rate for drug R&D had previously occurred using the
AGI method [2, 3].
EAGI was used to make in vivo antidepressive com-
parisons between MH and its parent FA or CSS (Figures
4 and 5) based on clinical results. For several centuries,
CSS has been used to clinically attenuate mood disorders
similar to depression or the TCM syndrome known as
“liver depression” [6]. Such comparisons resulted in the
production of antidepressive MH in the present study. When
gavaged acutely at high doses in rats, MH, FA, and CSS all
signiﬁcantly reduced immobility time by 23.5–28.2% (P<
0.05) and increased the numbers of crossing by 23.4–33.0%
(P<0.05), which is consistent with the results obtained
for Fluoxetine. The traditional clinical use of CSS played an
important role in discovering the novel antidepressive, MH.
Previous research had only implicated its use in anticancer
[25], antibacterial, and anticoagulation [26] treatments. In
contrast, AGI mainly involves the analysis in vitro activity
with less focus on holistic eﬃcacy, which is consistent with
thehighfailurerateofdrugR&Dduetopooreﬃcacy[1,24].
In conclusion, MH, a compound isolated from FA for
the ﬁrst time via BAGI, was detected by its structure spec-
tral data, and its antidepressive eﬀects were found to be
similar to FA and CSS. This result highlights the hit-to-lead
optimizationofadrugcandidate[31]andhelpedtoelucidate
the antidepressive mechanism of CSS.
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